As we age, the complexity of our health often increases, leading to the management of multiple chronic conditions. This reality gives rise to a phenomenon known as polypharmacy, or the simultaneous use of multiple medications in a single patient. Polypharmacy is a significant concern.

According to the National Diabetes Statistics Report, 5.7% of all United States (US) adults with type 1 diabetes rely on insulin for managing their condition. Additionally, approximately 12.3% of US adults started using insulin within a year of their diabetes diagnosis.

In the ever-evolving battle against infectious diseases, the rise of drug-resistant infections poses a significant challenge to global health. These resilient bugs have developed mechanisms to withstand conventional treatments, leaving scientists and healthcare professionals searching for innovative solutions.

Henrietta Lacks, an African-American woman, unknowingly contributed to one of the most significant advancements in medical science when cells taken from her cervical cancer biopsy in 1951 were used to create the first immortal human cell line, known as HeLa cells.

In the ever-evolving landscape of medical research, drug repurposing has emerged as a groundbreaking approach, proving that sometimes old dogs can indeed learn new tricks.  Drug repurposing, also known as drug repositioning or drug reprofiling, refers to the process of identifying new uses for existing drugs that are already approved for other indications.

COVID-19 began as an unexplained respiratory illness in Wuhan, China and quickly spread throughout the world, killing millions of people.